BioStock: Mendus steps up the clinical development in 2023

Mendus released its 2022 Annual Report this week, which refers to 2022 as a “breakthrough” year for the company. The milestones reached give Mendus the opportunity to prepare vididencel for the next phase of clinical development, reinitiate clinical development with its intratumoral primer ilixadencel, and make way for a new pipeline programme in the upcoming field of NK cell therapies. BioStock spoke with CEO Erik Manting to learn more

Read the interview with Erik Manting at biostock.se:

Mendus steps up the clinical development in 2023 - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/